400 Technology Sq
3 articles with Quench Bio
A little more than a year after securing $50 million in a Series A financing round, Quench Bio, an Atlas Venture company, is shutting down operations after failing to meet its therapeutic goals.
Quench Bio, a company driving new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, announced that it has been named by Fierce Biotech as one of 2020's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
Quench Bio, a company leveraging new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, announced the completion of a $50 million Series A financing led by RA Capital Management, with participation from new Investor Abbvie Ventures.